Hormonal modulation of ESR1 mutant metastasis.
Animals
Aromatase Inhibitors
/ pharmacology
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Dihydrotestosterone
/ pharmacology
Estradiol
/ metabolism
Estrogen Receptor alpha
/ genetics
Estrogens
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Mice
Mutation
/ genetics
Neoplasm Metastasis
Receptors, Androgen
/ drug effects
Tamoxifen
/ pharmacology
Xenograft Model Antitumor Assays
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
24
04
2020
accepted:
11
11
2020
revised:
31
10
2020
pubmed:
17
12
2020
medline:
31
7
2021
entrez:
16
12
2020
Statut:
ppublish
Résumé
Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transition (EMT) with cells exhibiting enhanced migration and invasion potential in vitro. When small subpopulations of Y537S ESR1 mutant cells were injected along with WT parental cells, tumor growth was enhanced with mutant cells becoming the predominant population in distant metastases. Y537S mutant primary xenograft tumors were resistant to the antiestrogen tamoxifen (Tam) as well as to estradiol (E
Identifiants
pubmed: 33323970
doi: 10.1038/s41388-020-01563-x
pii: 10.1038/s41388-020-01563-x
pmc: PMC8020875
mid: NIHMS1645970
doi:
Substances chimiques
AR protein, human
0
Aromatase Inhibitors
0
ESR1 protein, human
0
Estrogen Receptor alpha
0
Estrogens
0
Receptors, Androgen
0
Dihydrotestosterone
08J2K08A3Y
Tamoxifen
094ZI81Y45
Estradiol
4TI98Z838E
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
997-1011Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIEHS NIH HHS
ID : P42 ES027725
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008231
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA203690
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072038
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207270
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217842
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224083
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES030285
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER cancer statistics review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016. http://seer.cancer.gov/csr/1975_2013/ .
Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013;501:365–72.
pubmed: 24048069
pmcid: 24048069
Fuqua SA. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2001;6:407–17.
pubmed: 12013530
pmcid: 12013530
Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev. 2004;25:869–98.
pubmed: 15583021
pmcid: 15583021
Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell. 2018;33:173–86.e5.
pubmed: 29438694
pmcid: 29438694
Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997;57:1244–9.
pubmed: 9102207
pmcid: 9102207
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427–38.e6.
pubmed: 30205045
pmcid: 30205045
Fuqua SA, Gu G, Rechoum Y. Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat. 2014;144:11–9.
pubmed: 24487689
pmcid: 24487689
Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, et al. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016;157:253–65.
pubmed: 27178332
pmcid: 27178332
Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, et al. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res. 2015;166:540–53.e2.
pubmed: 26434753
pmcid: 26434753
Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7:313ra182.
pubmed: 26560360
pmcid: 26560360
O’Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8:1390–403.
pubmed: 30206110
pmcid: 30206110
Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2:1310–5.
pubmed: 27532364
pmcid: 27532364
De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121:1–11.
pubmed: 19533338
pmcid: 19533338
Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, et al. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERalpha-positive breast cancer. Breast Cancer Res Treat. 2015;154:225–37.
pubmed: 26487496
pmcid: 26487496
Rechoum Y, Rovito D, Iacopetta D, Barone I, Ando S, Weigel NL, et al. AR collaborates with ERalpha in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014;147:473–85.
pubmed: 25178514
pmcid: 25178514
Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, et al. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011;17:6510–21.
pubmed: 3281508
pmcid: 3281508
Park SH, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol. 2008;22:2085–98.
pubmed: 18550773
pmcid: 18550773
Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA. 2010;107:15449–54.
pubmed: 2932589
pmcid: 2932589
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics. 2015;8:54.
pubmed: 26297356
pmcid: 26297356
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–30.
pubmed: 24055055
pmcid: 24055055
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:1134–50.
pubmed: 26858339
pmcid: 26858339
Mihaly Z, Kormos M, Lanczky A, Dank M, Budczies J, Szasz MA, et al. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat. 2013;140:219–32.
pubmed: 23836010
pmcid: 23836010
Pidugu VK, Wu MM, Yen AH, Pidugu HB, Chang KW, Liu CJ, et al. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling. Oncogene. 2019;38:3232–47.
pubmed: 30626937
pmcid: 30626937
Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, et al. Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget. 2014;5:8429–41.
pubmed: 25238261
pmcid: 25238261
Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10:1349–55.
pubmed: 18820689
pmcid: 18820689
Chiang KC, Huang ST, Wu RC, Huang SC, Yeh TS, Chen MH, et al. Interferon alpha-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival. Cancer Manag Res. 2019;11:1893–905.
pubmed: 30881116
pmcid: 30881116
Jiang J, Liu W, Guo X, Zhang R, Zhi Q, Ji J, et al. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer. Oncogene. 2011;30:4498–508.
pubmed: 21602894
pmcid: 21602894
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
pubmed: 22522925
pmcid: 22522925
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–9.
pubmed: 19421193
pmcid: 19421193
Ponnusamy S, Asemota S, Schwartzberg LS, Guestini F, McNamara KM, Pierobon M, et al. Androgen receptor is a non-canonical inhibitor of wild-type and mutant estrogen receptors in hormone receptor-positive breast cancers. iScience. 2019;21:341–58.
pubmed: 31698248
pmcid: 31698248
Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017;8:1865.
pubmed: 29192207
pmcid: 29192207
Felipe JL, Nofech-Mozes S, Bayani J, Bartlett JM. EMT in Breast Carcinoma-A Review. J Clin Med. 2016;5:65. https://doi.org/10.3390/jcm5070065 .
doi: 10.3390/jcm5070065
Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol. 2007;21:2907–18.
pubmed: 17761946
pmcid: 17761946
Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, et al. Slug contributes to cancer progression by direct regulation of ERalpha signaling pathway. Int J Oncol. 2015;46:1461–72.
pubmed: 25652255
pmcid: 25652255
Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer Biol Ther. 2018;19:858–68.
pubmed: 29580128
pmcid: 29580128
Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Estevez L, et al. Results from a randomized placebo-controlled phase 2 trial evaluating exemestane±enzalutamide in patients with hormone receptor–positive breast cancer [abstract]. In: Proceedings of the 2017 San Antonio breast cancer symposium. Philadelphia, PA: AACR; 2018.
Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol. 2012;26:1252–67.
pubmed: 22745190
pmcid: 22745190
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16:R7.
pubmed: 24451109
pmcid: 24451109
Rangel N, Rondon-Lagos M, Annaratone L, Osella-Abate S, Metovic J, Mano MP, et al. The role of the AR/ER ratio in ER-positive breast cancer patients. Endocr Relat Cancer. 2018;25:163–72.
pubmed: 29386247
pmcid: 29386247
Narayanan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134–42.
pubmed: 28624515
pmcid: 28624515
Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, et al. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun. 2016;7:12991.
pubmed: 27694828
pmcid: 27694828
Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, et al. Loss of Rho GDIalpha and resistance to tamoxifen via effects on estrogen receptor alpha. J Natl Cancer Inst. 2011;103:538–52.
pubmed: 21447808
pmcid: 21447808
Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, et al. Proteomic profiling identifies key coactivators utilized by mutant ERalpha proteins as potential new therapeutic targets. Oncogene. 2018;37:4581–98.
pubmed: 29748621
pmcid: 29748621
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.
pubmed: 24157548
pmcid: 24157548
Kollipara RK, Kittler R. An integrated functional genomic analysis identifies the antitumorigenic mechanism of action for PPARgamma in lung cancer cells. Genom Data. 2015;3:80–6.
pubmed: 26484153
pmcid: 26484153
Lambert JR, Nordeen SK. Analysis of steroid hormone-induced histone acetylation by chromatin immunoprecipitation assay. In: Lieberman BA, editor. Steroid receptor methods: protocols and assays. Totowa, NJ: Humana Press; 2001. pp. 273–81.
Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, et al. SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer. 2019;5:16.
pubmed: 31231679
pmcid: 31231679
Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE. 2013;8:e82241.
pubmed: 24367507
pmcid: 24367507